Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacety...

Full description

Bibliographic Details
Main Authors: Alexandre Perla, Lívia Fratini, Paula S. Cardoso, Carolina Nör, André T. Brunetto, Algemir L. Brunetto, Caroline Brunetto de Farias, Mariane Jaeger, Rafael Roesler
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
medulloblastoma
ependymoma
glioma
histone deacetylase inhibitors
epigenetics
brain tumor
Online Access:https://www.frontiersin.org/article/10.3389/fcell.2020.00546/full
id doaj-656536c4d17a43e08d31ac160e2405b5
record_format Article
spelling doaj-656536c4d17a43e08d31ac160e2405b52020-11-25T03:47:51ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2020-07-01810.3389/fcell.2020.00546547200Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic PotentialAlexandre Perla0Alexandre Perla1Lívia Fratini2Lívia Fratini3Paula S. Cardoso4Paula S. Cardoso5Carolina Nör6Carolina Nör7André T. Brunetto8André T. Brunetto9Algemir L. Brunetto10Algemir L. Brunetto11Caroline Brunetto de Farias12Caroline Brunetto de Farias13Mariane Jaeger14Mariane Jaeger15Rafael Roesler16Rafael Roesler17Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilDepartment of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilDepartment of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilDepartment of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, BrazilThe Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, CanadaDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, CanadaCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilChildren’s Cancer Institute, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilChildren’s Cancer Institute, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilChildren’s Cancer Institute, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilChildren’s Cancer Institute, Porto Alegre, BrazilCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, BrazilDepartment of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, BrazilBrain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.https://www.frontiersin.org/article/10.3389/fcell.2020.00546/fullmedulloblastomaependymomagliomahistone deacetylase inhibitorsepigeneticsbrain tumor
collection DOAJ
language English
format Article
sources DOAJ
author Alexandre Perla
Alexandre Perla
Lívia Fratini
Lívia Fratini
Paula S. Cardoso
Paula S. Cardoso
Carolina Nör
Carolina Nör
André T. Brunetto
André T. Brunetto
Algemir L. Brunetto
Algemir L. Brunetto
Caroline Brunetto de Farias
Caroline Brunetto de Farias
Mariane Jaeger
Mariane Jaeger
Rafael Roesler
Rafael Roesler
spellingShingle Alexandre Perla
Alexandre Perla
Lívia Fratini
Lívia Fratini
Paula S. Cardoso
Paula S. Cardoso
Carolina Nör
Carolina Nör
André T. Brunetto
André T. Brunetto
Algemir L. Brunetto
Algemir L. Brunetto
Caroline Brunetto de Farias
Caroline Brunetto de Farias
Mariane Jaeger
Mariane Jaeger
Rafael Roesler
Rafael Roesler
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
Frontiers in Cell and Developmental Biology
medulloblastoma
ependymoma
glioma
histone deacetylase inhibitors
epigenetics
brain tumor
author_facet Alexandre Perla
Alexandre Perla
Lívia Fratini
Lívia Fratini
Paula S. Cardoso
Paula S. Cardoso
Carolina Nör
Carolina Nör
André T. Brunetto
André T. Brunetto
Algemir L. Brunetto
Algemir L. Brunetto
Caroline Brunetto de Farias
Caroline Brunetto de Farias
Mariane Jaeger
Mariane Jaeger
Rafael Roesler
Rafael Roesler
author_sort Alexandre Perla
title Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
title_short Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
title_full Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
title_fullStr Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
title_full_unstemmed Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
title_sort histone deacetylase inhibitors in pediatric brain cancers: biological activities and therapeutic potential
publisher Frontiers Media S.A.
series Frontiers in Cell and Developmental Biology
issn 2296-634X
publishDate 2020-07-01
description Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.
topic medulloblastoma
ependymoma
glioma
histone deacetylase inhibitors
epigenetics
brain tumor
url https://www.frontiersin.org/article/10.3389/fcell.2020.00546/full
work_keys_str_mv AT alexandreperla histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT alexandreperla histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT liviafratini histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT liviafratini histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT paulascardoso histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT paulascardoso histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT carolinanor histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT carolinanor histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT andretbrunetto histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT andretbrunetto histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT algemirlbrunetto histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT algemirlbrunetto histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT carolinebrunettodefarias histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT carolinebrunettodefarias histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT marianejaeger histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT marianejaeger histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT rafaelroesler histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
AT rafaelroesler histonedeacetylaseinhibitorsinpediatricbraincancersbiologicalactivitiesandtherapeuticpotential
_version_ 1724501682516131840

Similar Items